

More than 10 years of experience:
Trusted by top 20 pharma companies

OncoSignatureTM 2D/3D Cell Panel Screening


Do you need reliable data delivered quickly?

Rapidly generate high quality data to drive patient stratification, assess drug repurposing, discern molecular biomarkers or define mechanism of action for your 2021 therapeutics development programmes

Build a screen that fits your needs

Cell line collection

- Data on up to 300 cell lines delivered in 4 months
- Flexibility to customize with 300+ additional cell lines



Single drug screening or combination drug screening


- Single agent or combination screening
- Accommodates diverse therapeutic modalities (including oncolytic virus)




Large Biologic



Small Biologic



Diverse Solvents



Small Molecules




Synthetic RNA's - siRNA



Synthetic RNA's - Cas9

Viability Assay CellTiter-Glo[®] 2.0 (CTG 2.0)

- Plug-and-play CTG 2.0 readouts
- Incorporates T₀ controls for GI₅₀ calculation to discriminate cytotoxic vs. cytostatic effects



Why choose Horizon Discovery?

Scalable pricing model

Screening more compounds = lower cost per compound

Enable in depth bio-informatics analysis

OncoSignature cell panel shares 95% alignment with the Cancer Cell Line Encyclopaedia (CCLE)

Quality assurance

Screens run following SOPs (maintained in a QA database) & tracked with LIMS system




Increased confidence

STR authenticated cell line bank with repeat testing during screening

Reproducibility

Close monitoring of cell line response to control compounds

Production monitoring of CellTiter-Glo® 2.0 Viability Assay in Cell Panel Compound Screens



- Retrospective analysis to compare control compound responses in recent (2019) versus historical (2015) assay runs in ~ 100 cancer cell lines
- Response with time monitored using AUC (area under the dose response curve)
- Demonstrates excellent reproducibility over time

Cell line rotation



Click here to read our new blog



Check out this recent webinar: Advancing Cancer Drug Development Using 2D and 3D Cell Panel Screens

t +44 (0)1223 976 160 (UK) or +1 800 235 9880 (USA); +1 303 604 9499 (USA)

f +44 (0)1223 655 581

e info@horizondiscovery.com

w horizondiscovery.com/contact-us

Horizon Discovery, 8100 Cambridge Research Park, Waterbeach, Cambridge, CB25 9TL, United Kingdom

©2020 The Horizon logo and other trademarks are the property of Horizon Discovery Limited, unless otherwise stated. DHARMACON is a trademark of Dharmacon Inc. CellTiter-Glo® is a registered trademark of Promega.

horizonTM
INSPIRED CELL SOLUTIONS

V10920